Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Osimertinib for NSCLC With Uncommon EGFR Mutations
- Status
- SUSPENDED
- Phase
- N/A
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Status
- RECRUITING
- Phase
- PHASE3
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Status
- RECRUITING
- Phase
- PHASE2
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2